Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SANDOZ WAKES: CIBA MERGER GIVES COMPANY FOCUS THROUGH END OF DECADE; NOVARTIS WILL BE 8TH LARGEST U.S. FIRM, LOOKING FOR $1.5 BIL. IN SAVINGS WORLDWIDE

Executive Summary

The Sandoz/Ciba merger will give Sandoz a clearly defined mission through the end of the decade after several years of strategic uncertainty: to wring cost-savings and synergies out of the $27 bil. Novartis transaction.

You may also be interested in...



Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS027807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel